Labcorp Dividend and Market Update: Key Information Before Ex-dividend Date May 29, 2025
Generated by AI AgentAinvest Dividend Digest
Sunday, May 25, 2025 7:11 pm ET1min read
LH--
Labcorp has announced a dividend of $0.720 per share, with the ex-dividend date set for May 29, 2025, and payment scheduled for Jun 11, 2025. This latest dividend is higher than the average of the last ten dividends, which stood at $0.398 per share. The announcement was made on Apr 10, 2025. This cash dividend follows the company's prior payout on Mar 12, 2025, which also distributed $0.720 per share.
Recently, LabcorpLH-- has been the focus of considerable attention due to several significant developments. The company secured a $117.03 million contract modification for clinical reference laboratoryLAB-- testing services, continuing its collaboration with the U.S. Army Health Contracting Activity. This project is expected to run until Dec 31, 2025, and highlights Labcorp's strong position within the healthcare sector.
In addition, Labcorp's stock has seen a 16% increase in share price over the past month, partially attributed to its partnership with Frame, aimed at enhancing fertility solutions. Analysts have offered one-year price targets ranging from $248.00 to $300.00, with an average target price of $274.07, implying a potential upside from the current price of $242.53. The consensus recommendation from brokerage firms rates Labcorp as "Outperform," reflecting confidence in its growth prospects.
Furthermore, Labcorp's fundamentals remain robust, with the company paying out just 21% of its free cash flow in dividends last year, indicating a sustainable dividend policy. Analysts have recently noted Labcorp's withdrawal of its 2020 guidance and suspension of share buyback activities, decisions shaped by the impact of the coronavirus on first-quarter results.
The ex-dividend date of May 29, 2025, is crucial for investors, as it marks the deadline for purchasing Labcorp stock to receive the upcoming dividend. Any acquisitions made after this date will not qualify for the dividend payout.
Recently, LabcorpLH-- has been the focus of considerable attention due to several significant developments. The company secured a $117.03 million contract modification for clinical reference laboratoryLAB-- testing services, continuing its collaboration with the U.S. Army Health Contracting Activity. This project is expected to run until Dec 31, 2025, and highlights Labcorp's strong position within the healthcare sector.
In addition, Labcorp's stock has seen a 16% increase in share price over the past month, partially attributed to its partnership with Frame, aimed at enhancing fertility solutions. Analysts have offered one-year price targets ranging from $248.00 to $300.00, with an average target price of $274.07, implying a potential upside from the current price of $242.53. The consensus recommendation from brokerage firms rates Labcorp as "Outperform," reflecting confidence in its growth prospects.
Furthermore, Labcorp's fundamentals remain robust, with the company paying out just 21% of its free cash flow in dividends last year, indicating a sustainable dividend policy. Analysts have recently noted Labcorp's withdrawal of its 2020 guidance and suspension of share buyback activities, decisions shaped by the impact of the coronavirus on first-quarter results.
The ex-dividend date of May 29, 2025, is crucial for investors, as it marks the deadline for purchasing Labcorp stock to receive the upcoming dividend. Any acquisitions made after this date will not qualify for the dividend payout.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet